Baseline demographic, clinical and laboratory characteristics of the study population
| Adalimumab group (n=89) | Placebo group (n=91) | p Value between groups | |
|---|---|---|---|
| Age (years) | 56.2 (25.8–77.6) | 54.2 (28.3–76.7) | 0.71 |
| Female sex (%) | 63 | 69 | 0.46 |
| Disease duration (days) | 88 (42–162) | 83 (42–150) | 0.74 |
| Rheumatoid factor positive (%) | 70 | 74 | 0.67 |
| Anti-CCP positive (%) | 60 | 70 | 0.17 |
| Number of tender joints (0–40) | 15 (5–38) | 16 (6–34) | 0.78 |
| Number of swollen joints (0–40) | 10 (3–33) | 11 (3–31) | 0.66 |
| VAS-doctors global (0–100 mm) | 57 (27–89) | 51 (22–86) | 0.10 |
| VAS-pain (0–100 mm) | 63 (13–98) | 58 (13–92) | 0.21 |
| VAS-patient global (0–100 mm) | 70 (12–100) | 65 (17–96) | 0.27 |
| VAS-patient fatigue (0–100 mm) | 67 (9–94) | 54 (9–92) | 0.12 |
| s-CRP (7–161 mg/l) | 15 (7–133) | 15 (7–109) | 0.54 |
| DAS28CRP (1.7–8.7) | 5.5 (3.8–7.8) | 5.6 (3.8–7.3) | 0.53 |
p Values for differences between two treatment groups by Mann–Whitney U test or Fisher's exact test.
Anti-CCP, anticyclic citrullinated protein antibodies (in serum); DAS28CRP,Disease Activity Score; s-CRP, serum C-reactive protein; VAS, visual analogue scale.